ELI LILLY & Co (symbol: LLY) is the issuer of record for a Form 4 filing submitted to the SEC.
ELI LILLY & Co (LLY) director Ralph Alvarez reported an acquisition of common stock as compensation. On 2026-08-17, he received 10.4945 shares valued at $1183.16 per share, granted as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares after he leaves board service. Following this, he holds 55,744.788 shares directly and 758 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest.
ELI LILLY & Co (LLY) executive Patrik Jonsson, EVP & President, LLY International, reported selling 6,500 shares of common stock on 2026-08-17 at $1,175.10 per share in an open-market or private transaction. After this sale, he directly holds 54,146.62 shares and has an additional 632.40 shares held indirectly through a 401(k) plan. The sale was carried out under a Rule 10b5-1 trading plan adopted on February 17, 2026.
ELI LILLY & Co officer Donald A. Zakrowski, SVP, Finance, & CAO, reported selling 2,000 shares of common stock on 2026-08-10 at an average price of $1,185.01 per share in an open-market transaction. After this sale, he held 1,525.89 shares directly and 1,734.73 shares indirectly through a 401(k). The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
A holder of LLY common stock filed to potentially sell 2,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The planned sale has an aggregate market value of approximately $2,371,420.00 as of the filing details provided.
The shares to be sold were acquired on 02/10/2025 from the issuer as Restricted Stock Units and Performance Stock Units, and are now being registered for possible resale.
ELI LILLY & Co executive Anat Hakim, EVP, GC & Secretary, reported a sale of 5,000 shares of common stock on August 7, 2026 at $1,190.00 per share. The shares were held indirectly through her spouse, and she disclaims beneficial ownership except to the extent of her pecuniary interest. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2026. After the sale, 11,875 shares remained held indirectly by her spouse, 22,987.024 shares were held directly, and 15,700 shares were held indirectly through the Anat Hakim SLAT.
Eli Lilly and Company reported strong second-quarter 2026 results, with worldwide revenue of $22.97 billion, up 48% year over year on 60% higher volume, led by diabetes and obesity drugs Mounjaro and Zepbound. Reported EPS rose 26% to $7.94, and non-GAAP EPS increased 33% to $8.38.
Gross margin reached 85.8% of revenue, while net income grew to $7.1 billion despite $2.8 billion of acquired IPR&D and $703 million of acquisition-related charges. Key Products generated $15.7 billion in revenue, and Mounjaro alone delivered $9.9 billion, with Zepbound contributing $4.9 billion.
Full-year 2026 guidance was raised, with revenue now expected between $85 billion and $87 billion and performance margin targeted at 49.0%–50.5%. Non-GAAP EPS guidance was updated to $35.50–$36.50, reflecting strong underlying growth offset by $3.03 per share of acquired IPR&D charges.